What should be the primary target of "treat to target" in psoriatic arthritis?

What should be the primary target of "treat to target" in psoriatic arthritis?

<h4>Background</h4> <p>Treat to Target in psoriatic arthritis (PsA) recommendations have stated that the target should be remission or inactive disease. Potential definitions include Very Low Disease Activity (VLDA), PsA Disease Activity Score (PASDAS) near remission, Disease Act...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Coates, LC, Lubrano, E, Perrotta, FM, Emery, P, Conaghan, PG, Helliwell, PS
Format:	Journal article
Język:	English
Wydane:	Journal of Rheumatology 2018

Podobne zapisy

What should be the primary target of ‘treat to target’ in PsA?
od: Coates, L, i wsp.
Wydane: (2018)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
od: Coates, L, i wsp.
Wydane: (2022)

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial
od: Coates, L, i wsp.
Wydane: (2019)

Sustained very low disease activity and remission in psoriatic arthritis patients
od: Lubrano, E, i wsp.
Wydane: (2019)

New approved drugs for psoriatic arthritis
od: F.M. Perrotta, i wsp.
Wydane: (2016-09-01)

Precision medicine in psoriatic arthritis: how should we select targeted therapies?
od: Al-Mossawi, H, i wsp.
Wydane: (2019)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
od: Ennio Lubrano, i wsp.
Wydane: (2019-08-01)

How should we define disease and outcomes in axial psoriatic arthritis?
od: Coates, LC
Wydane: (2021)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
od: Ennio Lubrano, i wsp.
Wydane: (2023-07-01)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
od: P.S. Helliwell
Wydane: (2011-09-01)

The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
od: Coates, L, i wsp.
Wydane: (2017)

Does treat to target or achieving remission improve radiographic outcome in psa?
od: Coates, L, i wsp.
Wydane: (2016)

Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores
od: Weinstein, SM, i wsp.
Wydane: (2021)

Mixed methods study of clinicians’ perspectives on barriers to implementation of treat to target in psoriatic arthritis
od: Dures, E, i wsp.
Wydane: (2020)

Novel concepts in psoriatic arthritis management: Can we treat to target?
od: Tucker, L, i wsp.
Wydane: (2018)

Comparing the visual analogue scale and the numerical rating scale in patient-reported outcomes in psoriatic arthritis
od: Ye, W, i wsp.
Wydane: (2021)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
od: Gladman, DD, i wsp.
Wydane: (2022)

The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study
od: Helliwell, PS, i wsp.
Wydane: (2023)

Assessment of patient-physician interactions in psoriatic arthritis: national results of the ASSIST Study
od: Perrotta, FM, i wsp.
Wydane: (2024)

Measuring physical function in psoriatic arthritis: comparing the Multi-Dimensional Health Assessment Questionnaire to the Health Assessment Questionnaire Disability Index
od: Ye, W, i wsp.
Wydane: (2021)

Occult axial involvement in patients with psoriatic arthritis mutilans: a case report
od: F.M. Perrotta, i wsp.
Wydane: (2019-07-01)

Current concepts and unmet needs in psoriatic arthritis
od: Mahmood, F, i wsp.
Wydane: (2017)

Psoriatic arthritis: prospects for the future
od: Hackett, S, i wsp.
Wydane: (2022)

Should methotrexate have any place in the treatment of psoriatic arthritis?
od: Ye, W, i wsp.
Wydane: (2019)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
od: Helliwell, PS, i wsp.
Wydane: (2021)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
od: Coates, L, i wsp.
Wydane: (2016)

Measuring outcomes in psoriatic arthritis
od: Ogdie, A, i wsp.
Wydane: (2020)

Outcome measures in psoriatic arthritis: where next?
od: Hackett, S, i wsp.
Wydane: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
od: Ennio Lubrano, i wsp.
Wydane: (2022-12-01)

Assessing disease activity in psoriatic arthritis: a literature review
od: Tucker, L, i wsp.
Wydane: (2018)

Psoriatic arthritis: lessons from imaging studies and implications for therapy
od: Mathew, A, i wsp.
Wydane: (2016)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
od: Mease, PJ, i wsp.
Wydane: (2020)

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial
od: Helliwell, P, i wsp.
Wydane: (2019)

Cost-effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of a multicenter randomized controlled trial
od: O'Dwyer, J, i wsp.
Wydane: (2018)

Identification of psoriatic arthritis in patients with psoriasis
od: Coates, LC, i wsp.
Wydane: (2023)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
od: Soriano, ER, i wsp.
Wydane: (2023)

Remission in psoriatic arthritis—where are we now?
od: Coates, L, i wsp.
Wydane: (2017)

Psoriatic arthritis: imaging techniques
od: E. Lubrano, i wsp.
Wydane: (2012-06-01)

Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
od: Coates, L, i wsp.
Wydane: (2018)

Psoriatic arthritis
od: FitzGerald, O, i wsp.
Wydane: (2021)